In phase III NEOPAN study presented by Dr. Ducreux, FOLFIRINOX improved progression-free survival (PFS) compared to gemcitabine in #locally_advanced unresectable #pancreatic_cancer. However, no significant difference in overall survival (OS) was observed between the arms. At a median follow-up of 41.1 months, the median PFS with FOLFIRINOX was 9.7 months vs 7.5 months with gemcitabine (HR=0.57, p=.0468). The median OS was 15.1 months with FOLFIRINOX vs 15.6 months with gemcitabine (HR=1.03, p=0.66).
.png)